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by immunization wNNith sedimentable materials
inactivated with formalin. Further data
will be presented on the effect of immuniza-
tion on other parameters of infection such
as viraemia and changes in antibody titres
during the course of the disease.
SURFACE IMMUNOLOGICAL MARK-
ERS IN ACUTE MYELOBLASTIC LEU-
KAEMIA. G. M. TAYLOR, C. B. FREEMAN,
J. ESCUDER and R. HARRIS, Department of
Medical Genetics, St Mary's Hospital, Man-
chester.
Before treatment, peripheral blood leuco-
cytes from patients with acute myeloblastic
leukaemia (AML) form few T and B cell
rosettes compared with normal individuals,
and AML blasts do not themselves form
rosettes, unlike a minority of cases of acute
lymphoblastic leukaemia in which T rosette
forming cells are known to occur. A large
but variable proportion of peripheral leuco-
cytes from patients with untreated AML
possess surface immunoglobulin detected by
both direct and indirect immunofluorescence.
The pattern of fluorescent staining on
AML blasts differs from that seen on CLL
cells, and also in contrast in vitro with anti-
human immunoglobulin serum. Surface im-
munoglobulin on AML blasts may represent
tumour associated antibody or immune
complex.
Our results suggest that the proportion
of rosette forming cells, and of cells with
surface immunoglobulin can be used as a
diagnostic aid for patients with AML.
TISSUE CULTURE OF MALIGNANT
EFFUSIONS AND THEIR USEFUL-
NESS AS TARGET CELLS IN CYTO-
TOXICITY CELLS. R. H. WHITEHEAD,
University Department of Surgery, Welsh
National School of Medicine, Cardiff.
Breast tumours pose special problems for
those seeking to study the immune respon-
siveness of patients to their tumours. It is
difficult, if not impossible, to culture breast
cancer cells itn vitro. This has led previous
workers studying lymphocyte cytotoxicity
to use cells derived from effusions from
patient,s Mwithl advanced breast cancer. This
wN-as donie )ecause of thle belief that pleuri:al
effusion cells were free of fibroblasts and
were most probably tumour cells.
Comparative cytotoxicity tests have been
performed using cells derived from pleural
effusions from breast cancer patients and
cells derived from ascites from colon car-
cinoma patients. Cells derived from a
malignant melanoma have also been used
as target cells. Lymphocytes from patients
with breast cancer, colon cancer and melan-
oma have been tested against their cells.
These tests failed to show any tumour
specific cytotoxicity (except in the case of
melanoma), suggesting that the cells derived
from these effusions are ofnormal origin.
CELL MEDIATED IMMUNOREACTI-
VITY IN HUMAN LUNG NEOPLASIA.
B. M. VOSE and M. MOORE, Immunology
Department, Paterson Laboratories, Man-
chester.
The relative susceptibilities of various
tissue culture cells derived principally from
malignant, normal and foetal lung tissues,
to cytolysis by leucocytes from patients with
different histological types of lung cancer
were investigated using an in vitro micro-
cytotoxicity assay for cell mediated im-
munity.
Target cells derived from 12- to 17-week
old embryo lungs and from pulmonary
tumours of different histological types were
most susceptible to the cytotoxic action of
lung cancer patients' leucocytes, while a
lower but significant frequency of positive
reactions has also been observed against
cells originating from non-malignant pul-
monary tissue.
It is concluded that lung tumour cells
may express tumour associated antigens
but their nature and specificity remain to
be elucidated.
AN ATTEMPT TO IDENTIFY STIMU-
LATORY SUBSTANCES INTERFER-
ING WITH A TWO STAGE MACRO-
PHAGE MIGRATION INHIBITION
(MMI) ASSAY AND TO ASSESS IM-
MUNOCOMPETENCE. J. G. AASKOV
and H. M. ANTHONY, Department of Ex-
perimental Pathology and Cancer Researchl,
University of Leeds.
An iInlprove(l two-stage MIA11 test lhas
b)eeli developed to ineasure the primiary
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response to cellular antigens by peripheral
lymphocytes from normal and lung cancer
patients in serum free medium in vitro
(Aaskov and Anthony, Biomedicine, 1973,
19, 369). In common with results published
for the one-stage MMI test, occasional
stimulation of migration has been noted
in this assay. Because of the problem of
assaying migration inhibition factor (MIF)
in the presence of stimulatory material,
attempts have been made to identify the
materials responsible for this stimulation.
Sephadex chromatography yielded an
MIF (mol. wt 20-30,000) and a chemotactic
factor (protein, mol. wt approximately
12,500) from supernates of antigenically
stimulated lymphocytes. The chemotactic
material had no stimulatory effect on
macrophage migration. Stimulation of mi-
gration was observed in fractions from
2 peaks (mol. wt >150,000 and mol. wt
60-70,000). Assay after isoelectric focusing
has shown this to be due to Hb and IgG.
The stimulatory effect of these substances
at certain concentrations has been confirmed.
SPLEEN SIZE IN PATIENTS WITH
BREAST CANCER. J. G. ROBERTS, M.
WISBEY, K. G. LEACH and M. BAUM, Depart-
ments of Surgery and Medical Physics,
Welsh National School of Medicine and the
University Hospital of Wales.
Gamma camera images of the spleen
obtained following the intravenous injection
of heat damaged, autologous, 99Tcm labelled
red cells provide a means of estimating
spleen size in patients.
A new method of calculating spleen size
has been validated in 10 patients. The
computed weight correlated well with the
exsanguinated weight of the excised spleens
(r = 0 9894) wNith 9500 confidence limits
of less than 50 g. This technique has been
applied to 40 patients with breast cancer
and 5 controls. The cancer patients had
significantly larger spleens (P < 0.05) and
spleen size varied with clinicopathological
stage. In 10 patients spleen size has been
estimated at primary treatment and some
6 months later. All patients except one
showed a reduction in spleen size (P < 0 01).
These results suggest that in man, as in
experimental animals, splenomegaly occurs
as a component of the host response to
cancer.
IMMUNITY IN PATIENTS WITH
BREAST CANCER. A. J. COCHRAN, R. M.
MACKIE, C. E. Ross, R. M. GRANT and
D. E. HOYLE, University Department of
Pathology, Western Infirmary, Glasgow.
We have examined tumour directed
immunity and nonspecific immunological
activities in 200 patients with breast car-
cinoma. Techniques employed included skin
testing with recall antigens, the leucocyte
migration technique (LMT), mitogen induced
transformation, an immune adherence tech-
nique, immunoglobulin and complement
assays and T and B cell quantification.
The main findings are: (1) A majority
of breast cancer patients (54%0) showed
evidence of sensitization to tumour derived
materials; (2) sensitization is rare in control
donors (15%). This is true of normal
donors, patients with simple breast disease
and those with other malignancies; (3) in-
hibition of migration was similarly frequent
with homologous (53o%) and autologous
(56%) combinations of antigens and leuco-
cytes; (4) sensitization is less commonly
demonstrable in patients with advanced
disease (27%0); (5) patients with local recur-
rences were as frequently reactive as those
with primary tumours only (60%); (6)
extracts of mastopathic breasts only rarely
inhibited the migration ofleucocytes whether
from cancer patients (210%) or controls
(170%); (7) there is some evidence that
non-cancerous tissues in cancerous breasts
may possess tumour-like antigens. The sig-
nificance of these results, obtained mainly
with the LMT, can be assessed by relating
them to results obtained by the other
techniques.
THE RELATIONSHIP BETWEEN
PROGNOSIS AND LYMPHOCYTE
RESPONSE TO PHA IN BREAST
CANCER. P. M. BOLTON, R. H. WHITE-
HEAD, R. G. NEWCOMBE, S. L. JAMES and
L. E. HUGHES, Departments of Surgery and
Medical Statistics, Welslh National School of
Medicine, Cardiff.
Studies of lymphocyte response to PHA
in cancer patients have shown variable
results, probably due to methodological
differences. We have used a microtest
method with 3 PHA dose levels (0*3 ,ug/ml,
0*8 ,ug/ml and 40) ,ug/ml) to study the
lymphocyte response in 119) patients witl
breast disease. These patients wi-ere classi-